

## **Attachment 8 – List of HOPS Study Publications**

During the previous 3 year OMB approval period, the HIV Outpatient (HOPS) enrolled 157 new HIV positive patients and produced the following 11 publications addressing multiple domains in HIV-infection and treatment relating to the goals of the National HIV/AIDS Strategy (Centers for Disease Control and Prevention)

1. Novak RM, Hart RL, Chmiel JS, Brooks JT, Buchacz K; HIV Outpatient Study (HOPS) Investigators. Disparities in initiation of combination antiretroviral treatment and in virologic suppression among patients in the HIV Outpatient Study (HOPS), 2000-2013. *J Acquir Immune Defic Syndr*. 2015 Sep 1; 70(1); 23-32.
2. Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT; and the HIV Outpatient Study Investigators. Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. *J Acquir Immune Defic Syndr*. 2015 Jul 1;69(3):306-311
3. Buchacz K, Wiegand R, Armon C, Chmiel JS, Wood K, Brooks JT, Palella FJ Jr. Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study. *HIV Clin Trials*. 2015 Aug; 16(4): 139 – 46.
4. Buchacz K, Young B, Palella FJ Jr, Armon C, Brooks JT; HIV Outpatient Study (HOPS) investigators; HIV Outpatient Study HOPS investigators. Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naïve persons in the HIV Outpatient Study, 1999-2011. *J Antimicrob Chemother*. 2015 Aug; 70(8):2337-46.
5. Young B, Hart R, Buchacz K, Scott M, Palella F, and Brooks JT. for the HIV Outpatient Study (HOPS). HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed combination antiretroviral therapy. *J Int Assoc Provid AIDS Care*. 2015 Nov – Dec; 14(6): 536-43.
6. Sheth AN, Ofotokun I, Buchacz K, Armon C, Chmiel JS, Hart RL, Baker R, Brooks JT, Palella FJ Jr. Antiretroviral regimen durability and success in treatment-naïve and treatment-experienced patients by year of treatment initiation, United States, 1996-2011. *J Acquir Immune Defic Syndr*. 2016 Jan 1; 71(1): 47 – 56.

7. Battalora L, Buchacz K, Armon C, Overton ET, Hammer J, Patel P, Chmiel JS, Wood K, Bush TJ, Spear JR, Brooks JT, Young B; HIV Outpatient Study (HOPS) and SUN Study Investigators. Low bone mineral density and risk of incident fracture in HIV-infected adults. *Antivir Ther.* 2016 Jan; 21(1): 45-54.

8. Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, Hart R, Wei SC, Loustalot F, Brooks JT, Buchacz K. Cardiovascular disease risk prediction in the HIV Outpatient Study. *Clin Infect Dis.* 2016 Dec 1;63(11):1508-1516.

9. Palella Jr F J; Armon C; Chmiel JS; Brooks JT; Hart R; Lichtenstein K; Novak RM; Yangco B; Wood K; Durham M; Buchacz K; CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm<sup>3</sup> and mortality risk. *Journal of Antimicrobial Chemotherapy*, June 20 2016.

10. Durham MD, Hart R, Buchacz K, Hammer J, Young B, Yang D, Wood K, Yangco B, Brooks JT, the HOPS Investigators. Antiretroviral nonadherence and condomless sex in the HIV Outpatient Study, USA, 2007–2014. *International Journal of STD & AIDS*, January 2017 [Epub ahead of print].

11. Samandari T, Tedaldi E, Armon C, Hart R, Chmiel JS, Brooks JT, Buchacz K, and the HIV Outpatient Study Investigators. Incidence of Hepatitis C Virus Infection in the Human Immunodeficiency Virus Outpatient Study Cohort, 2000–2013. *Open Forum Infect Dis.* 2017 Jun 10; 4 (2)